Key facts
- Notable investors include Immortal Dragons.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for R3 Bio (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for R3 Bio (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About R3 Bio (Biotechnology)
Developer of a regenerative medicine incubation studio intended for addressing the critical challenge of blood vessel formation in engineered tissues. The company's studio offers a combination of 3D bioprinting, induced pluripotent stem cells (iPSCs), and novel biomaterials to create vascularized liver tissue with proper cellular architecture and function, enabling patients to be treated with biomaterials for metabolic optimization and genetic interventions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Ownership
- Privately Held (backing)
R3 Bio (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in R3 Bio (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on R3 Bio (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.